Furthermore, preferential sites of lung cancer metastases in vivo exhibit significantly higher levels of CXCL12 protein expression compared with that of the primary tumor or plasma levels, indicating that a chemotactic gradient may be established between the site of the primary tumor and metastatic sites (14). The gene discussed is CXCL12; the disease is lung carcinoma.